TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20180042916A1
SERIAL NO

15701157

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The subject invention provides for methods of reducing the relapse rate and/or reducing the accumulation of physical disability in a relapsing-remitting multiple sclerosis human patient, the method comprising orally administering to the patient a daily dose of 0.6 mg laquinimod.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
TEVA PHARMACEUTICAL INDUSTRIES LTD124 DVORA HANEVI 'A ST TEL AVIV 6944020

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bar-Zohar, Dan Muttenz, CH 15 91
Kofler, Dina Kadima-Zoran, IL 9 73
Tarcic, Nora Modiin, IL 48 366

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation